All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.
Professor Sagar Lonial is currently the Chief Medical Officer at the Winship Cancer Institute of Emory University, Atlanta, US. He is also a Professor and Chair of the Department of Hematology and Medical Oncology at the Emory University School of Medicine, Atlanta, US.
Professor Lonial is internationally recognized as a leading authority in multiple myeloma treatment and research, having recently received a Lifetime Achievement Award for Outstanding Contributions to Hematology-Oncology from the Indo-American Cancer Association. As a medical oncologist, he treats patients with multiple myeloma and is a leading member of the bone marrow transplantation and clinical trials team. He has recently spent time developing the B-cell malignancy program with respect to novel targeted agents in laboratory models as well as early clinical trials.
Professor Lonial obtained his medical degree from the University of Louisville School of Medicine, Louisville, US, which was followed by a residency at the Baylor College of Medicine, Houston, US, and a fellowship in hematology and oncology at the Emory University School of Medicine, Atlanta, US.